Fig. 2From: Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)a ACR20, b ACR50, and c ACR70 responses over 84 weeks (full analysis set; NRI). ACR20/50/70, 20/50/70% improvement in American College of Rheumatology criteria; NRI, nonresponder imputation; QD, once dailyBack to article page